KRAS and colorectal carcinoma: In BRAF V600E-mutant CRC, tumor cells often exhibit an initial response to BRAF inhibitors, but frequently develop resistance through reactivation of the MAPK pathway, commonly via KRAS amplification or MEK mutations [76].